The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2023
The phase 3 ENHANCE-2 trial examining the frontline combination of magrolimab and azacitidine vs physician’s choice of venetoclax with azacitidine or intensive chemotherapy in patients with acute myeloid leukemia and TP53 mutations has been discontinued, according to an announcement from Gilead Sciences.
25th Annual International Lung Cancer Congress®
Register Now!
BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers
View More
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis
View More
Burst CME: Regulatory Approval Pathways for Influenza Vaccines
View More
Medical Crossfire®: Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs
View More
Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult
View More
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?
View More
"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
European Commission Approves Enrylaze for ALL and Lymphoblastic Lymphoma
September 22nd 2023The European Commission has granted marketing authorization for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month and older who developed hypersensitivity or silent inactivation to E. coli–derived asparaginase.
Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.
Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML
The European Commission has approved oral decitabine and cedazuridine for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for standard induction chemotherapy.
EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia
The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.
Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for CD30+ Stage III Hodgkin Lymphoma
The European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.
TKI Selection in CML Demands Nuanced Approaches
Choosing the most effective TKIs for individual patients with chronic myeloid leukemia requires decision making based on efficacy data, agent safety profiles, and patient characteristics, according to Michael Deininger, MD.
CHMP Releases Positive Opinion for Quizartinib in Newly Diagnosed FLT3-ITD+ AML
September 15th 2023The Committee for Medicinal Products for Human Use has recommended the approval of quizartinib in the European Union for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by maintenance quizartinib, for adult patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.
Golidocitinib NDA Under NMPA Review for Relapsed/Refractory PTCL
The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of golidocitinib for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.
JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis
September 12th 2023Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Quizartinib Improves OS Irrespective of Allo-HCT in CR1 and Pre-Allo MRD Status in FLT3-ITD+ AML
Quizartinib plus standard intensive induction and consolidation therapy resulted in improved overall survival compared with placebo in patients with newly diagnosed, FLT3-ITD–positive AML irrespective of allogeneic hematopoietic cell transplantation in first complete remission and pre-allo minimal residual disease status.
Subcutaneous Epcoritamab Elicits Durable Responses in Relapsed/Refractory LBCL
Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma, with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AML
September 8th 2023The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.
Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches
September 8th 2023Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.
Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL
September 8th 2023Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.
Follicular Lymphoma: Patient Monitoring and Maintenance Therapy
Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.
Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML
September 7th 2023No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.
Understanding How to Best Measure MRD Negativity in Ph+ ALL
September 7th 2023The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL
Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.
Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML
Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML
September 7th 2023The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.